Claro Advisors’s Editas Medicine EDIT Stock Holding History

Claro Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-50	Closed	-$2K	–	369
2018 Q4	$2K	Buy	+50	New	+$1.36K	﹤0.01%	911

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

OTPPB

Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

Claro Advisors's EDIT Position: Q1 2019 in Review

Claro Advisors sold out of Editas Medicine (EDIT) in Q1 2019, closing a stake of 50 shares — an estimated $2K sold.

Claro Advisors first reported a position in EDIT in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 201 funds tracked by Wall St. Rank hold EDIT as of Q1 2019.

Claro Advisors reported no remaining Editas Medicine position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 50 Editas Medicine shares in Q1 2019, an estimated $2K.
Claro Advisors first reported a position in Editas Medicine in Q4 2018 and held it in 1 quarter.
Claro Advisors's Editas Medicine position peaked at $2K in Q4 2018.
201 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.